ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,000,356 | +84.1% | 10,683 | +75.5% | 0.12% | +77.9% |
| Q2 2023 | $543,354 | +59.8% | 6,088 | +141.0% | 0.07% | +83.8% |
| Q4 2021 | $340,000 | -52.5% | 2,526 | -53.6% | 0.04% | -42.2% |
| Q2 2021 | $716,000 | -40.9% | 5,439 | -42.1% | 0.06% | -39.0% |
| Q1 2021 | $1,211,000 | +133.8% | 9,394 | +202.3% | 0.10% | +169.2% |
| Q4 2020 | $518,000 | – | 3,108 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |